Tag: tenecteplase
ESO taskforce provides forecast for European launch of stroke thrombolysis drugs
The European Stroke Organisation (ESO) Executive Committee’s Thrombolysis Taskforce has provided “important updates” regarding the security of supply for Metalyse (tenecteplase) and Actilyse (alteplase)...
Varied tenecteplase data may provide clarity on the drug’s exact role...
This year’s European Stroke Organisation Conference (ESOC; 15–17 May, Basel, Switzerland) saw a plethora of data on intravenous tenecteplase—from studies spanning Australia, Canada, China,...
Phil White
Phil White’s career as a physician and researcher has seen him play a role in numerous major stroke trials, and serve as an educator...
Tenecteplase deemed a safe and feasible adjunct to thrombectomy in ALLY...
Intra-arterial tenecteplase has demonstrated potential as a safe and feasible adjunct to mechanical thrombectomy in patients with acute ischaemic stroke caused by a distal...
Tenecteplase deemed non-inferior to alteplase in suitable ischaemic stroke patients
The ATTEST-2 trial has found that tenecteplase was non-inferior to alteplase, the more established of the two thrombolytic agents, in suitable acute ischaemic stroke...
Vision recovery among potential benefits of endovascular therapy in PCA occlusion...
A multicentre study presented at the recent European Stroke Organisation Conference (ESOC; 24–26 May, Munich, Germany) has found that vision recovery and an increased...
New data represent “fantastic news” in IVT despite lack of efficacy...
Results from the TIMELESS trial represent “fantastic news” on the safety of intravenous tenecteplase in selected late-window stroke patients, despite the drug failing to...
Tenecteplase linked to higher haemorrhage rates than alteplase in no-thrombectomy stroke...
Intravenous tenecteplase was associated with a higher rate of intracranial haemorrhage (ICH), as compared to alteplase, in a recent analysis of real-world data from...
Chinese TRACE II trial deems tenecteplase non-inferior to alteplase in ischaemic...
New data on intravenous tenecteplase indicate that it can achieve comparable efficacy and safety to alteplase in treating stroke—and, as such, may be used...
European Stroke Organisation taskforce delivers update on thrombolytic drug shortages
The thrombolysis taskforce of the European Stroke Organisation (ESO) executive committee has provided an update on current shortages of alteplase and tenecteplase, detailing outcomes...
World Stroke Congress bolsters evidence on optimal thrombectomy and thrombolysis approaches
While much-needed improvements to existing triage and transport protocols for acute stroke patients were a leading topic of focus on World Stroke Day (29...
Tenecteplase offers “incredible opportunity” to optimise thrombolytic stroke treatments
Earlier this year, results from the Canadian AcT (Alteplase compared to tenecteplase) randomised controlled trial (RCT) were delivered for the first time at the...
US study bolsters recent evidence supporting tenecteplase in ischaemic stroke care
Tenecteplase, a newer-generation intravenous thrombolysis (IVT) drug, has outperformed the traditional treatment (alteplase) for ischaemic strokes in several key areas, demonstrating better health outcomes...
Tenecteplase shown to be effective for acute ischaemic stroke in large...
In what is claimed to be the largest stroke clinical trial ever run in Canada, researchers have shown that tenecteplase—a safe, well-tolerated drug commonly...
Newer clot-busting medication may someday increase time window for stroke treatment
In a phase 2a clinical trial in China, the clot-busting medication tenecteplase has been shown to be effective in restoring blood flow to the...
Tenecteplase reduces the need for thrombectomy compared to alteplase
Results from the Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke (EXTEND-IA TNK) study show that the use of tenecteplase (0.25mg/kg) led to...
